Related Experiment Videos
Increased plasma transforming growth factor-beta1 in migraine
Kumiko Ishizaki1, Takao Takeshima, Yoko Fukuhara
1Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan.
Headache
|September 24, 2005
Summary
Transforming growth factor-beta1 (TGF-beta1) levels were significantly elevated in migraine patients during headache-free periods. This suggests TGF-beta1 may contribute to the development of migraine headaches.
Area of Science:
- Neuroscience
- Immunology
- Pain Research
Background:
- Migraine involves peripheral and central sensitization, with neurogenic inflammation being crucial.
- Transforming growth factor-beta1 (TGF-beta1), a proinflammatory cytokine, is investigated for its role in migraine.
Purpose of the Study:
- To investigate plasma levels of TGF-beta1 in migraine patients during headache-free intervals.
- To explore the potential involvement of TGF-beta1 in the pathophysiology of migraine.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to determine TGF-beta1 levels.
- Platelet-poor plasma (PPP) was collected from 68 migraine patients (with and without aura), 58 healthy controls, and 12 episodic tension-type headache subjects during headache-free periods.
Main Results:
- TGF-beta1 levels in PPP were significantly higher in migraine patients (2.62 ng/mL) compared to controls (1.80 ng/mL) and tension-type headache subjects (2.08 ng/mL).
- Statistical analysis (ANOVA, post hoc tests) confirmed the significant elevation of TGF-beta1 in migraine patients (P=.007).
Conclusions:
- Plasma TGF-beta1 levels are significantly increased in migraine patients even when they are not experiencing a headache.
- These findings indicate that TGF-beta1 may play a role in the underlying mechanisms contributing to migraine development.